arrow
M

Mary Ann Anderson

The Royal Melbourne Hospital
H指数:46
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel

基于早期axicabtagene ciloleucel扩增的R/R LBCL动态风险分层

2026-09-080
OAAI
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.

长期生存期后CD19 CAR-T治疗期间持续且病原体特异性的感染风险:一项澳大利亚多中心队列研究

2026-06-240
PRE
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma

维奈托克和伊布替尼诱导边缘区淋巴瘤产生持久的临床反应

2025-12-150
OAAI
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病中中枢神经系统受累:ERIC(欧洲慢性淋巴细胞白血病研究倡议)国际回顾性研究

2025-10-280
OAAI
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies

zanubrutinib在del(17p)和/或TP53 CLL/SLL患者治疗中的应用:临床研究分析

2025-08-220
OAAI
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial

流感特异性T细胞对疫苗接种的反应与基础血液恶性肿瘤无关:一项随机流感疫苗接种试验的分析

2025-07-010
PRE
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins

对渗透的血癌细胞进行再评估试验,测试维奈克拉或选择性靶向促生存BCL2蛋白的其他BH3模拟剂

2025-04-090
OA